Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 76
- Registration Number
- NCT02411825
- Locations
- 🇩🇪
Investigational Site Number 276001, Berlin, Germany
Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT02404558
- Locations
- 🇯🇵
Investigational Site Number 392001, Sendai-Shi, Japan
🇯🇵Investigational Site Number 392002, Sendai-Shi, Japan
🇯🇵Investigational Site Number 392003, Sendai-Shi, Japan
Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 253
- Registration Number
- NCT02401243
- Locations
- 🇨🇦
Investigational Site Number 124004, Victoria, Canada
🇨🇦Investigational Site Number 124026, Vancouver, Canada
🇨🇦Investigational Site Number 124006, Vancouver, Canada
A Study Assessing the Safety and Effectiveness of FEX60/PE10 Fixed Combination Tablet in Patients With Allergic Rhinitis
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 105
- Registration Number
- NCT02401191
- Locations
- 🇯🇵
Sanofi Administrative Office, Tokyo, Japan
Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide
- Conditions
- Prostate Cancer Metastatic
- Interventions
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 8
- Registration Number
- NCT02379390
- Locations
- 🇨🇦
Investigational Site Number 124005, Hamilton, Canada
🇨🇦Investigational Site Number 124002, Montreal, Canada
🇨🇦Investigational Site Number 124009, Quebec, Canada
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 91
- Registration Number
- NCT02373202
- Locations
- 🇯🇵
Investigational Site Number 392039, Fukuoka-Shi, Japan
🇯🇵Investigational Site Number 392006, Sasebo-Shi, Japan
🇯🇵Investigational Site Number 392023, Takaoka-Shi, Japan
Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 327
- Registration Number
- NCT02345070
- Locations
- 🇺🇸
Investigational Site Number 840017, Atlanta, Georgia, United States
🇺🇸Investigational Site Number 840009, Minneapolis, Minnesota, United States
🇺🇸Investigational Site Number 840013, Stony Brook, New York, United States
Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 443
- Registration Number
- NCT02343926
- Locations
- 🇷🇺
Investigational Site 03, Vladimir, Vladimirskaya Oblast, Russian Federation
Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia
- Conditions
- Pneumonia
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 161
- Registration Number
- NCT02332577
- Locations
- 🇫🇷
Investigational Site Number :250010, Grenoble, France
🇫🇷Investigational Site Number :250029, Avoine, France
🇫🇷Investigational Site Number :250015, COLOMBES Cedex, France
Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 369
- Registration Number
- NCT02332590
- Locations
- 🇺🇸
Investigational Site Number 840403, Saint Petersburg, Florida, United States
🇺🇸Investigational Site Number 840229, Coral Gables, Florida, United States
🇺🇸Investigational Site Number 840140, Tampa, Florida, United States